Tybourne Capital Management HK Ltd. Purchases New Shares in Cellebrite DI Ltd. (NASDAQ:CLBT)

Tybourne Capital Management HK Ltd. acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 115,615 shares of the company’s stock, valued at approximately $1,947,000. Cellebrite DI makes up about 0.5% of Tybourne Capital Management HK Ltd.’s investment portfolio, making the stock its 23rd largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Cellebrite DI by 59.6% in the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after acquiring an additional 1,017 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after purchasing an additional 1,742 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new position in Cellebrite DI in the 2nd quarter valued at $71,000. Pathway Financial Advisers LLC increased its position in shares of Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Cellebrite DI during the 2nd quarter worth $103,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

CLBT has been the subject of several research reports. Lake Street Capital increased their price target on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. TD Cowen lifted their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their price objective on Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Needham & Company LLC boosted their target price on Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI presently has an average rating of “Buy” and a consensus price target of $20.29.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $19.89 on Thursday. The firm has a market capitalization of $4.10 billion, a P/E ratio of -12.83, a PEG ratio of 2.72 and a beta of 1.50. Cellebrite DI Ltd. has a one year low of $7.91 and a one year high of $21.00. The business has a fifty day moving average price of $18.12 and a 200-day moving average price of $15.03.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same quarter last year, the company earned $0.09 EPS. The firm’s revenue was up 27.0% compared to the same quarter last year. Sell-side analysts expect that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.